Physician profile
Scott Terry Keller
NPI 1609861830
$688.53
in general payments reported to CMS, 2019-2025
14 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $194 · 2023: $272 · 2024: $106 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $134.13 | 2022-2025 | |
| Lilly USA, LLC | $116.03 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.41 | 2023-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $69.79 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $58.72 | 2022-2025 | Shingrix |
| Merz North America, INC. | $45.27 | 2023 | Xeomin |
| Abbvie INC. | $37.59 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $29.81 | 2022-2025 | Gardasil 9, Capvaxive |
| Corcept Therapeutics | $22.57 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.72 | 2022 | |
| Vivus LLC | $18.62 | 2022 | |
| Amgen INC. | $17.07 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.22 | 2022 | |
| Medicure Pharma INC. | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.